Replies to post #45523 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

Jerry Treppel, Chairman and CEO of Elite commented, “The Company continues to progress towards its goal of becoming break-even on an operating cash flow basis exclusive of any clinical trials required for our abuse-resistant opioid products. We expect this to occur in the next quarter or two. We are in the process of finalizing and scaling up the formulation of one of our abuse-resistant opioid products so as to commence human trials. As we have stated before, we are in the process of seeking additional capital to finance these trials. All in all, it was another excellent quarter of progress for Elite. ”